Skip to main content
. 2021 Nov 17;9(3):e01131-21. doi: 10.1128/Spectrum.01131-21

FIG 2.

FIG 2

Sensitivity (%) of SARS-CoV-2 FMIA and the effect of time post-onset of symptoms (DPO). (A) Anti-S (SFL and RBD) IgG FMIA. (B) Anti-N IgG FMIA. (C) Anti-S (SFL and RBD) IgA FMIA. (D) Anti-S (SFL) IgM FMIA. RBD, receptor binding domain of SARS-CoV-2 (Wuhan-Hu-1) spike glycoprotein; SFL, full-length spike glycoprotein of SARS-CoV-2 (Wuhan-Hu-1); N, SARS-CoV-2 nucleoprotein of SARS-CoV-2 (Wuhan-Hu-1).